苑东生物：盐酸乙哌立松片获药品注册证书

Core Viewpoint - The company Yuandong Biotech (688513.SH) announced that its wholly-owned subsidiary Chengdu Shode Pharmaceutical Co., Ltd. has received the drug registration certificate from the National Medical Products Administration for its product, Etifoxine Hydrochloride Tablets [1] Group 1: Product Information - The drug Etifoxine Hydrochloride Tablets is primarily indicated for improving muscle tension states associated with conditions such as cervical shoulder-arm syndrome, periarthritis of the shoulder, and low back pain [1] - Additional indications include treatment for spastic paralysis caused by cerebrovascular disorders, spastic myelopathy, cervical spondylosis, postoperative sequelae (including brain and spinal cord tumors), and post-traumatic sequelae (such as spinal cord injury and head trauma) [1] - The drug is also indicated for conditions like amyotrophic lateral sclerosis, infantile cerebral palsy, spinocerebellar degeneration, spinal vascular disorders, subacute optic neuritis myelitis (SMON), and other brain and spinal cord diseases that lead to spastic paralysis [1]